Turing Pharmaceuticals said that it has received a no objection letter from Health Canada regarding the initiation of Phase 1 trials of TUR-002 intranasal ketamine for the reduction of suicidal ideations and that it expects to complete the trials by mid-2016.
The timing is in line with a November 2015 announcement from Turing that was made prior to the arrest and ouster of the company’s controversial CEO, Martin Shkreli.
Turing President of Research and Development Eliseo Salinas said, “I am very impressed with the progress Turing’s R&D team has made in a very short time frame advancing intranasal ketamine for the treatment of suicidality.”
Read the Turing press release.
